SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical, has received approval for its innovative drug, Naldemedine. The approval from the Guangdong Medical Products Administration allows for an early launch in the Guangdong-Hong Kong-Macao Greater Bay Area to treat opioid-induced constipation (OIC).
SBP Group's subsidiary received approval to launch its innovative drug Naldemedine in the Guangdong-Hong Kong-Macao Greater Bay Area, targeting a new market for its opioid-induced constipation treatment.
The approval was granted by the Guangdong Medical Products Administration, SBP Group (01177.HK) announced on Tuesday.
The drug, Naldemedine, is exclusively licensed by SBP's subsidiary, Chia Tai Tianqing Pharmaceutical. It is indicated for the treatment of opioid-induced constipation (OIC), a common side effect for patients undergoing pain management therapy.
This regulatory green light opens up a significant new revenue stream for SBP Group within the large Greater Bay Area market. The approval could lead to a positive re-evaluation of the company's stock, which saw short selling of $83.51 million, representing 16.25% of its volume, as of April 9.
The introduction of Naldemedine in this new region provides a fresh catalyst for SBP Group's pharmaceutical sales. Investors will be watching for initial sales figures from the Greater Bay Area, which will be a key indicator of the drug's market acceptance and future revenue contribution.
This article is for informational purposes only and does not constitute investment advice.
